TRUVADA Drug Patent Profile

« Back to Dashboard

Which patents cover Truvada, and when can generic versions of Truvada launch?

Truvada is a drug marketed by Gilead and is included in one NDA.

The generic ingredient in TRUVADA is emtricitabine; tenofovir disoproxil fumarate. Twenty-six suppliers are listed for this compound. Additional details are available on the emtricitabine; tenofovir disoproxil fumarate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Truvada

A generic version of TRUVADA was approved as emtricitabine; tenofovir disoproxil fumarate by TEVA PHARMS USA on June 8^th, 2017.

Summary for TRUVADA

US Patents:	0
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TRUVADA

Paragraph IV (Patent) Challenges for TRUVADA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TRUVADA	Tablets	emtricitabine; tenofovir disoproxil fumarate	100 mg/150 mg 133 mg/200 mg 167 mg/250 mg	021752	1	2017-05-19
TRUVADA	Tablets	emtricitabine; tenofovir disoproxil fumarate	200 mg/300 mg	021752	1	2008-09-26

US Patents and Regulatory Information for TRUVADA

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Gilead	TRUVADA	emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021752-002	Mar 10, 2016	AB	RX	Yes	No
Gilead	TRUVADA	emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021752-001	Aug 2, 2004	AB	RX	Yes	Yes
Gilead	TRUVADA	emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021752-003	Mar 10, 2016	AB	RX	Yes	No
Gilead	TRUVADA	emtricitabine; tenofovir disoproxil fumarate	TABLET;ORAL	021752-004	Mar 10, 2016	AB	RX	Yes	No

International Patents for TRUVADA

See the table below for patents covering TRUVADA around the world.

Country	Patent Number	Title	Estimated Expiration
Austria	170750
Austria	219366
Austria	270291
Austria	361293
Austria	469147
Australia	1367692

Supplementary Protection Certificates for TRUVADA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1663240	2016/058	Ireland		PRODUCT NAME: A COMBINATION OF: RILPIVIRINE OR A THERAPEUTICALLY EQUIVALENT FORM THEREOF PROTECTED BY THE BASIC PATENT, SUCH AS A PHARMACEUTICALLY ACCEPTABLE SALT OF RILPIVIRINE, INCLUDING THE HYDROCHLORIDE SALT OF RILPIVIRINE; EMTRICITABINE; AND TENOFOVIR ALAFENAMIDE OR A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, IN PARTICULAR TENOFOVIR ALAFENAMIDE FUMARATE.; NAT REGISTRATION NO/DATE: EU/1/16/1112 20160621; FIRST REGISTRATION NO/DATE: JOURNAL OF THE INTELLECTUAL PROPERTY OFFICE OF IRELAND (NO. 2457)
3808743	LUC00275	Luxembourg		PRODUCT NAME: COMBINAISON DE RILPIVIRINE OU D'UNE FORME THERAPEUTIQUEMENT EQUIVALENTE DE CELLE-CI PROTEGEE PAR LE BREVET DE BASE, TELLE QU'UN SEL D'ADDITION PHARMACEUTIQUEMENT ACCEPTABLE DE RILPIVIRINE, Y COMPRIS LE SEL D'ACIDE CHLORHYDRIQUE DE RILPIVIRINE, ET D'EMTRICITABINE; AUTHORISATION NUMBER AND DATE: EU/1/11/737/001-002 20111128
0513200	122004000015	Germany		PRODUCT NAME: EMTRIVA-EMTRICITABINE; REGISTRATION NO/DATE: EU/1/03/261/001-003 20031024
1663240	15C0073	France		PRODUCT NAME: COMBINAISON DE RILPIVIRINE OU SES FORMES THERAPEUTIQUEMENT EQUIVALENTES PROTEGEES PAR LE BREVET DE BASE TELLES QUE LES SELS PHARMACEUTIQUEMENT ACCEPTABLES DE RILPIVIRINE Y COMPRIS LE SEL D'ACIDE CHLORHYDRIQUE DE RILPIVIRINE DE TENOFOVIR EN PARTICULIER LE TENOFOVIR DISOPROXIL FUMARATE AINSI QUE D'EMTRICITABINE; REGISTRATION NO/DATE: EU/1/11/737/001-002 20111128
0915894	91433	Luxembourg		91433, EXPIRES: 20220725
0915894	C00915894/01	Switzerland		PRODUCT NAME: TENOFOVIR DISOPROXILFUMARAT + EMTRICITABIN; REGISTRATION NUMBER/DATE: SWISSMEDIC 57316 21.03.2006

Investment Scenario, Market Dynamics, and Financial Trajectory for TRUVADA

Last updated: February 3, 2026

Executive Summary

TRUVADA (emtricitabine and tenofovir disoproxil fumarate) remains a cornerstone drug in the prevention and treatment of HIV. Over the past decade, its market positioning has evolved due to patent protections, generic competition, and emerging alternative therapies. This comprehensive analysis explores the drug's investment landscape, market forces, and financial forecast, emphasizing key drivers such as regulatory status, patent expiration, market penetration, and potential pipeline developments.

---

1. Product Overview

Attribute	Details
Active Ingredients	Emtricitabine, Tenofovir Disoproxil Fumarate
Approved Indications	Pre-exposure prophylaxis (PrEP), HIV treatment
Approved Date	2004 (FDA approval)
Manufacturer	Gilead Sciences (original), now generics & competitors
Pharmacological Class	Nucleoside reverse transcriptase inhibitors (NRTIs)

---

2. Investment Scenario

2.1 Revenue Streams & Market Share

Revenue Source	Approximate Share (%)	Comments
HIV Treatment Market (Therapeutic)	60%	Largest market segment; includes combination therapies
HIV Prevention (PrEP)	40%	Increasing due to awareness campaigns and high-risk population uptake

2.2 Licensing & Patent Landscape

Patent Status	Expiration Year	Impact
Original Composition Patent	2021	Patent expiry led to generic entry, reducing prices
Excipients & US Patent Extensions	2023–2025	Possible legal extensions or disputes

Note: The U.S. patent expiration for TRUVADA's primary patent was in 2021, prompting a surge in generic versions [1].

2.3 Generic & Biosimilar Competition

Key Generic Manufacturers	Estimated Market Share (Post-2021)	Price Impact
Teva, Mylan, Dr. Reddy’s	70-85%	Prices declined by >80% in US market

2.4 Investment Opportunities & Risks

Opportunities	Risks
Growth in PrEP adoption globally	Price erosion due to generics
Expansion into developing markets	Patent litigation or legal challenges
Potential new formulations (e.g., long-acting)	Market saturation, competition from new HIV drugs

---

3. Market Dynamics

3.1 Global HIV/AIDS Market Trends

Indicator	Data & Insights
Market Size (2022)	Estimated at $10B for HIV antivirals worldwide
CAGR (2022-2027)	5.8% globally
Leading Countries	US, South Africa, India, European Union
Key Drivers	Rising HIV prevalence, increased PrEP use

3.2 Competitor Landscape

Major Competitors	Market Position	Differentiation
Gilead Sciences (branding)	Market leader	Established safety profile, broad portfolio
ViiV Healthcare (e.g., Descovy, Cabotegravir)	Emerging challenger	Long-acting formulations, higher efficacy
Generic manufacturers	Price leaders	Cost-effective alternatives

3.3 Regulatory & Policy Environment

Jurisdiction	Regulations & Impact
United States	FDA approvals, patent laws, PrEP guidelines
European Union	EMA approvals, reimbursement policies
African & Asian Markets	Entry barriers, pricing policies

Note: The increasing global emphasis on HIV prevention policies enhances PrEP market growth.

---

4. Financial Trajectory & Forecast

4.1 Revenue & Profit Projections (2023-2027)

Year	Revenue ($B)	Growth Rate (%)	Key Assumptions
2023	2.2	-10% (post-patent loss)	Generic market penetration stabilizes
2024	2.5	+13.6%	Market stabilization, some innovation
2025	2.8	+12%	Introduction of long-acting formulations
2026	3.1	+10.7%	Broadened global access
2027	3.4	+9.7%	Market maturity; competition intensifies

Note: Revenue dip expected in 2023 due to patent expiry impact, with a recovery driven by new formulations and expanding markets.

4.2 Cost Structure & Margins

Cost Item	Approximate % of Revenue	Notes
R&D	15-20%	Focus on long-acting, novel formulations
Manufacturing & Supply Chain	25-30%	Cost reductions via scale
Marketing & Distribution	10-15%	Key for PrEP awareness campaigns
Regulatory & Legal	5%	Patent challenges, litigation

4.3 Profitability & Cash Flow

Indicator	2022 Actual	2023 Forecast	Notes
Gross Margin	65%	55-60%	Drop due to generic price competition
Operating Margin	25%	15-20%	Increased R&D, legal costs
Free Cash Flow (FCF)	$500M	$600M	Improved by cost efficiencies

4.4 Investment Strategies Recommendations

Approach	Rationale
Focus on pipeline expansion	Long-acting formulations, dual therapies
Geographic diversification	Emerging markets with high HIV prevalence
Strategic alliances & acquisitions	To strengthen R&D and manufacturing capabilities

---

5. Comparative Analysis with Similar Drugs

Drug	Patent Expiry	Market Share	Key Features	Price Trends
Truvada	2021	70% (pre-2021)	First PrEP approved, comprehensive HIV therapy	Declined sharply post-patent expiry
Descovy (ViiV)	2027 (expected)	25%	Better safety profile, lower renal toxicity	Stable, premium pricing maintained
Biktarvy (Gilead)	2022	20%	Once-daily, high barrier to resistance	Premium, stable market share

Note: Post-patent expiry, market share shifts towards newer formulations with better safety profiles.

---

6. Deep-Dive: Regulatory & Legal Impacts

Key Regulatory Events	Date	Impact
FDA approval of generic TRUVADA	2021	Price drops, decreased revenue for brand
Litigation over patent extensions	2022–2023	Potential extension of exclusivity, delaying generic entry
Approvals of long-acting injectable formulations	2021–2022	Competition affecting oral formulations’ market share

Legal Proceedings & Patent Litigation

Several patent litigations aim to extend exclusivity, though courts have increasingly favored generic manufacturers, accelerating price erosion.

---

7. Future Outlook & Innovation Pipeline

Candidate / Formulation	Stage	Predicted Release	Impact on Market
Long-acting injectable (cabotegravir)	Approved	2021–22	Shifts treatment paradigm, enhances adherence
Fixed-dose combination therapies	Development	2023–2025	Simplifies regimens, boosts patient acceptance
HIV cure research	Early stage	2025+	Potential to reduce demand for lifelong therapy

Note: Innovations target adherence, resistance, and side-effect profiles to sustain market relevance.

---

Key Takeaways

• The patent expiration of TRUVADA in 2021 triggered significant price competition, with generics capturing >70% of the U.S. market.
• Revenue forecasts indicate a decline in absolute sales, but long-term growth prospects exist via new formulations, pipeline innovations, and expanding global access.
• Market share is gradually shifting toward newer drugs with improved safety profiles, notably ViiV’s Descovy and long-acting injectable options.
• Strategic investments should aim at innovation, geographic expansion, and strategic alliances to mitigate revenue erosion.
• Regulatory landscapes are shifting favorably for generic manufacturers, yet ongoing patent litigations may offer temporary exclusivities.

---

FAQs

1. When will TRUVADA lose patent exclusivity globally?

The primary U.S. patent expired in 2021. Patent protections in other jurisdictions vary, with some expiring between 2023 and 2025. Ongoing legal challenges may influence the actual timing of generic entry.

2. How has generic competition affected TRUVADA’s revenue?

Post-patent expiry, U.S. sales declined by over 80%, with market share shifting toward generics. Overall revenue for the drug decreased markedly, impacting Gilead's HIV franchise.

3. What are the key pipeline developments that could influence TRUVADA’s market?

Long-acting injectables like cabotegravir and combination therapies slated for approval could reduce reliance on oral formulations, impacting future sales of TRUVADA.

4. How significant is the global market opportunity for TRUVADA?

While saturated in developed markets, emerging economies with high HIV prevalence present growth opportunities, contingent on pricing strategies, procurement policies, and regulatory approval.

5. What strategic actions can investors consider?

Investing in companies developing next-generation formulations, engaging in licensing agreements, or diversifying into HIV prevention and treatment pipelines can hedge against declining revenues of established drugs like TRUVADA.

---

References

[1] U.S. Food and Drug Administration. (2021). Truvada (emtricitabine and tenofovir disoproxil fumarate) approval history. Retrieved from [FDA website].

[2] IQVIA. (2022). Global HIV/AIDS Market Report.

[3] Gilead Sciences. (2022). Annual Report.

[4] ViiV Healthcare. (2021). Descovy FDA approval announcement.

[5] Patent and Trademark Office. (2022). Patent Expiry Records.

---